Axsome Therapeutics

AXS-14 (esreboxetine) is a small-molecule norepinephrine transporter inhibitor in Phase 3 development by Axsome Therapeutics for fibromyalgia. The active ingredient is reboxetine, a selective noradrenaline reuptake inhibitor previously approved in Australia under the brand name EDRONAX. Axsome is evaluating AXS-14 as a potential treatment for fibromyalgia, a chronic pain condition affecting millions globally. The program is currently active with the most recent milestone dated February 9, 2026. The clinical trial NCT07398417 is underway to support efficacy and safety in the fibromyalgia population. Reboxetine has established regulatory approval history in Australia, with listings dating to 2002 and a recent 2024 listing under Pfizer Australia. The Phase 3 development pathway positions AXS-14 to potentially address an underserved fibromyalgia market where multiple competitors are also advancing therapies. Axsome's strategy leverages the known pharmacology of reboxetine while pursuing a focused indication in pain management.

Fibromyalgia remains a significant unmet medical need affecting an estimated 2-4% of the global population, characterized by widespread musculoskeletal pain, fatigue, and sleep disturbance. Current treatment options are limited, with only a handful of FDA-approved medications, creating substantial commercial opportunity for effective new therapies. AXS-14 addresses this market gap by repurposing reboxetine, a compound with established safety data, into a focused fibromyalgia indication. The norepinephrine transporter inhibition mechanism offers a distinct pharmacological approach compared to existing fibromyalgia treatments. The competitive landscape includes multiple Phase 3 programs (TNX-102 SL from Tonix Pharmaceuticals, Erenumab from United Therapeutics Europe, and Xyrem from Jazz Pharmaceuticals), indicating robust industry interest and validation of fibromyalgia as a commercially viable indication. Success in Phase 3 could position AXS-14 as a differentiated option in a growing therapeutic category. The patient population—predominantly women aged 30-60 with chronic pain—represents a substantial addressable market with high treatment burden and significant quality-of-life impact. Regulatory approval would expand Axsome's portfolio and establish the company in the pain management space.

Drug Class: Selective noradrenaline reuptake inhibitor (SNRI)

Mechanism of Action: Inhibition of the sodium-dependent noradrenaline transporter, increasing synaptic norepinephrine availability

Modality: Small molecule

Active Ingredient: Reboxetine (INN)

Brand Name History: EDRONAX (approved in Australia)

Target: Sodium-dependent noradrenaline transporter (NET)

Route of Administration: Not yet disclosed

Therapeutic Class: Not yet disclosed

Related Therapies: Reboxetine has prior approval in Australia for depression-related indications; the AXS-14 program represents a new indication development strategy

First Approval History: Reboxetine (EDRONAX) was first listed in the Australian Register of Therapeutic Goods on May 1, 2002, under Pfizer Australia Pty Ltd sponsorship, with a subsequent listing on September 1, 2024

Patent Status: Not yet disclosed

United States (FDA): Regulatory status not yet disclosed. AXS-14 is in Phase 3 development; no IND, NDA, or approval status is documented in the facts provided.

European Union (EMA): Regulatory status not yet disclosed.

Japan (PMDA): Regulatory status not yet disclosed.

China (NMPA): Regulatory status not yet disclosed.

Australia (TGA): Reboxetine (EDRONAX) holds approved status in the Australian Register of Therapeutic Goods under Pfizer Australia Pty Ltd, with listings dated May 1, 2002 (PBS code 14474T) and September 1, 2024 (PBS code 8583R). This prior approval provides regulatory precedent for the active ingredient but does not constitute approval of AXS-14 for fibromyalgia.

Regulatory Strategy: Axsome's development pathway leverages the established safety profile of reboxetine while pursuing a new indication in fibromyalgia through Phase 3 clinical trials.

Strategic Positioning: Axsome's decision to repurpose reboxetine for fibromyalgia leverages existing safety and pharmacology data, potentially reducing development risk and accelerating time to market compared to de novo drug discovery. The Phase 3 status indicates the program has cleared Phase 2 efficacy gates and is advancing toward potential regulatory submission.

Competitive Implications: AXS-14 enters a crowded Phase 3 fibromyalgia landscape. Success will depend on differentiation through efficacy, tolerability, or convenience versus TNX-102 SL, Erenumab, and Xyrem. The norepinephrine mechanism offers mechanistic diversity, which may appeal to patients with inadequate response to existing therapies.

Regulatory Catalysts: Phase 3 trial readout (expected timing not disclosed) will be the critical near-term catalyst. Positive efficacy and safety data could support NDA/BLA filing. The prior approval of reboxetine in Australia may facilitate regulatory discussions regarding safety database adequacy.

Commercial Considerations: Fibromyalgia represents a multi-billion-dollar market opportunity. Peak sales projections are not yet disclosed, but successful approval would position AXS-14 as a differentiated option in a high-unmet-need indication. Axsome's lack of disclosed partnerships suggests potential for independent commercialization or future licensing opportunities.

Development Risks: Phase 3 failure, competitive pressure from earlier approvals, and reimbursement challenges in fibromyalgia remain key risks. The mechanism's relationship to depression treatment (reboxetine's original indication) may require careful positioning to differentiate AXS-14 as a pain therapy.